The recent PACIFIC trial assessing the anti‐PD‐L1 agent durvalumab as consolidation after thoracic chemoradiotherapy in NSCLC patients demonstrated an improved OS compared to placebo (Antonia et al., 2018). This evidence concerns the gene CD274 and non-small cell lung carcinoma.